Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Seeks To Resolve First Amendment Suit By Pacira

This article was originally published in The Gray Sheet

Executive Summary

Judge extends date for agency response to firm's complaint as parties continue settlement talks; case reveals two chinks in FDA’s off-label regulatory regime armor, former FDA advisor says.


Related Content

FDA Focusing Enforcement Efforts on GMP Compliance As Off-Label Prosecutions Wane
Pacira Drug Promotion Suit Settled With Broad Concessions From FDA
Device Firms Should Not Ignore Pharma Off-Label Suits, Experts Say
Off-Label Promotion Ruling Increases Pressure For FDA Policy Change


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts